Pharmaceutical News

RSS

Chemistry team discovers environmentally-friendly iron-based nanoparticle catalysts

A chemistry team at the University of Toronto has discovered environmentally-friendly iron-based nanoparticle catalysts that work as well as the expensive, toxic, metal-based catalysts that are currently in wide use by the drug, fragrance and food industry.

28 Mar 2012

Dr. Reddy’s introduces Quetiapine fumarate tablets in the U.S.

Dr. Reddy's Laboratories announced today that it has launched Quetiapine fumarate tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg), a bioequivalent generic version of SEROQUEL tablets in the US market on March 27, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Quetiapine fumarate tablets.

28 Mar 2012

ECTS, IOF publish guidance document to manage GIO

Oral glucocorticoids are commonly prescribed for a wide variety of disorders, most commonly for rheumatoid arthritis, obstructive pulmonary disease and inflammatory bowel diseases. However, the use of these medications can result in rapid bone loss during the first three to six months of therapy, leading to increased risk of fragility fractures.

28 Mar 2012

Non-HDL-C levels appear to increase risk of heart attack or stroke in statin-treated patients

Levels of non-high-density lipoprotein cholesterol (non-HDL-C) among statin-treated patients appears to be associated with the risk of developing a major cardiovascular event, such as a heart attack or stroke, as are levels of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, according to a meta-analysis of data from previously published studies appearing in the March 28 issue of JAMA.

28 Mar 2012

New pre-clinical data on Rexahn's RX-3117 study to be presented at AACR meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.

28 Mar 2012

Specific precautions must be taken for individuals on longer-term oral glucocorticoid therapy

Millions of people around the world are prescribed glucocorticoids for a wide variety of inflammatory conditions, including, rheumatoid arthritis, asthma and inflammatory bowel diseases. Although they are effective and widely used, one of the potentially serious side effects of these medications is glucocorticoid-induced osteoporosis.

28 Mar 2012

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

An experimental drug that acts in a novel way to lower cholesterol proved even more effective than statins and had few undesirable side effects, newly released data shows. The drug acts by modifying the way cholesterol levels are naturally controlled. A protein produced in the liver helps limit the amount of LDL, or “bad” cholesterol, that liver cells can remove from the bloodstream. The new drug, called REGN727, is a monoclonal antibody, made in a laboratory, that blocks the action of that protein.

27 Mar 2012

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF (Atrial fibrillation) patients, and as additional therapy to conventional antiplatelet therapy in ACS (Acute coronary syndrome) patients.

27 Mar 2012

Morning after pills difficult for teenagers to procure

Quite a few U.S. pharmacies may give teen girls incorrect information over the phone about whether they can get the morning-after pill. The pill is a form of emergency contraception taken within 72 hours after unprotected sex to prevent pregnancy without a prescription, a new study suggests.

27 Mar 2012

Surfaxin receives FDA approval for prevention of RDS in premature infants

The U.S. Food and Drug Administration today approved Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS), a breathing disorder that affects premature infants.

27 Mar 2012

Boniva generics receive FDA approval for treatment, prevention of osteoporosis

The U.S. Food and Drug Administration today approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause.

27 Mar 2012

New method uses E. coli bacteria to engineer human therapeutic glycoproteins

Escherichia coli - a bacteria considered the food safety bane of restaurateurs, grocers and consumers - is a friend. Cornell University biomolecular engineers have learned to use E. coli to produce sugar-modified proteins for making pharmaceuticals cheaper and faster.

27 Mar 2012

Teva, IVAX receive FDA approval for generic Lexapro to treat depression and GAD

The U.S. Food and Drug Administration today approved the first generic Lexapro (escitalopram tablets) to treat both depression and generalized anxiety disorder in adults.

27 Mar 2012

MedImmune receives FDA approval for FluMist Quadrivalent vaccine

FluMist Quadrivalent, a vaccine to prevent seasonal influenza in people ages 2 years through 49 years, has been approved today by the U.S. Food and Drug Administration. FluMist Quadrivalent is the first influenza vaccine to contain four strains of the influenza virus, two influenza A strains and two influenza B strains.

27 Mar 2012

Simple placebo pill can track footprints of prior antidepressant use

Individuals with major depressive disorder (MDD) often undergo multiple courses of antidepressant treatment during their lives. This is because the disorder can recur despite treatment and because finding the right medication for a specific individual can take time.

27 Mar 2012

UC professor to show new anticancer agent at ACS Spring 2012 meeting

Advances in chemotherapy have dramatically improved the outlook for many cancer patients, but the side effects of this treatment are daunting. A new generation of chemotherapy drugs with fewer side effects is the goal of Edward J. Merino, assistant professor of chemistry at the University of Cincinnati.

27 Mar 2012

Hapten licenses HPT-721 to prevent poison ivy dermatitis

Hapten Sciences Inc. of Memphis, Tenn., has licensed a compound developed by ElSohly Laboratories Inc. and University of Mississippi pharmaceutical researchers to prevent reactions to poison ivy, oak and sumac.

27 Mar 2012

Pharmaplan, Moberg Derma to distribute Nalox/Emtrix in South Africa

Moberg Derma AB has entered into a distribution agreement with Pharmaplan (Pty) Ltd. for Nalox//Emtrix - for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.

27 Mar 2012

Scientist develops a way to encase nutraceuticals in food-based products

A Purdue University food scientist has developed a way to encase nutritional supplements in food-based products so that one day consumers might be able to sprinkle vitamins, antioxidants and other beneficial compounds right onto their meals.

27 Mar 2012

Intravenous immune globulin effective treatment for GBS, CIDP

Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating polyneuropathy (CIDP), according to a guideline issued by the American Academy of Neurology.

27 Mar 2012